30.00
-0.46(-1.51%)
Currency In USD
| Previous Close | 30.46 |
| Open | 29.94 |
| Day High | 30.77 |
| Day Low | 29.33 |
| 52-Week High | 38.33 |
| 52-Week Low | 2.01 |
| Volume | 105,608 |
| Average Volume | 155,496 |
| Market Cap | 47.92M |
| PE | -2.48 |
| EPS | -12.11 |
| Moving Average 50 Days | 25.78 |
| Moving Average 200 Days | 10.98 |
| Change | -0.46 |
If you invested $1000 in Galecto, Inc. (GLTO) since IPO date, it would be worth $80 as of February 21, 2026 at a share price of $30. Whereas If you bought $1000 worth of Galecto, Inc. (GLTO) shares 5 years ago, it would be worth $96.77 as of February 21, 2026 at a share price of $30.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
GlobeNewswire Inc.
Feb 12, 2026 9:01 PM GMT
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its
Galecto Announces Pricing of $275 Million Underwritten Public Offering
GlobeNewswire Inc.
Feb 11, 2026 3:42 AM GMT
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
GlobeNewswire Inc.
Feb 10, 2026 9:04 PM GMT
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commen